PATENT CLAIM ANALYSIS

Application Number: 16075932
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "394000"]

Abstract:
The present invention is related to diagnostic, treatment and compound screening methods related to dry age-related macular degeneration (dry AM D). In select embodiments, the methods comprise determining expression or activity levels of NAD-dependent deacetylase sirtuin-1 (SI RT-1), AM P-activated protein kinase (AM PK), poly(adenosine diphosphate ribose) poly-merase-2 (PARP2), peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC-Iα) and/or mRNA levels of RAC-gamma serine/threonine-protein kinase (AKT3). In general, higher levels of PARP2, lower levels of PGC-Iα or AKT3 and/or higher acetylation levels of PGC-Iα in the samples are indicative that the subject or cells from which the samples are obtained are susceptible or are suffering from dry AMD.

Claim (Index 29):
The method of  claim 26  wherein the compound that induces expression of PGC-1\u03b1 is a sartan.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 96.0
- Lexical Diversity: 1.71053
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12583073', '15485997', '14746221', '10773446', '11660986']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7809941307283377
- 35 USC 102 Novelty (BERT): 0.5220914388943901
- Combined Prediction Score: 0.7551038615449429
- Mean Citation Score: 258.177182
- Max Citation Score: 271.42883
- Similarity Product: 147.10133635418777

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test